Cáncer de mama triple negativo asociado a dermatomiositis paraneoplásica: Reporte de caso y revisión de la literatura.
DOI:
https://doi.org/10.35509/01239015.707Palabras clave:
Dermatomiositis, Sindrome paraneoplásico, Carcinoma de mama triple negativo, fenómeno de Raynaud, quimioterapia, terapia citotóxica, corticoesteroideResumen
La dermatomiositis (DM) es un tipo de miopatía inflamatoria bien definida, inmunomediada, con afectación específica del músculo esquelético y con compromiso variable de piel y otros órganos. Se caracteriza por debilidad muscular proximal, lesiones cutáneas patognomónicas de dermatomiositis como el signo de Gottron, eritema violáceo o heliotropo, y evidencia de inflamación muscular por enzimas elevadas, cambios miopáticos en electromiografía y biopsia muscular anormal. Tiene una asociación bien establecida con diferentes tipos de cáncer pero es rara su asociación con cáncer de mama. Cuando se presentan de manera concomitante, su diagnóstico requiere un estudio multidisplinario para orientar el origen paraneoplásico frente a una etiología propiamente autoinmune que requiera terapia inmunosupresora dirigida. Describimos el caso de una paciente con diagnóstico simultáneo de cáncer de mama triple negativo y criterios de dermatomiositis como manifestación paraneoplásica.
Referencias bibliográficas
Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292 (8): 403-7.
Linklater H, Pipitone N, Rose MR, Norwood F, Campbell R, Salvarani C, et al. Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31 (5):767-9.
Bottai M, Tiärnlund A, Santoni G, Weth V, Pilkington C, de Visser M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 2017; 14; 3 (2): e000507. doi: 10.1136/rmdopen-2017-000507.
Leclair V, Lundberg I. New myositis classification criteria-what we have learned since Bohan and Peter. Curr Rheumatol Rep 2018
Stertz O. Polymyositis. Berl Klin Wochenschr 1916; 53:489
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292:344.
Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med 1976; 84:68
Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd. Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 1986; 61:645.
Sigurgeirsson B, Lindelöf B, Edhag O, Allander E. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326:363.
Stockton D, Doherty VR, Brewster DH. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85:41.
Yang Z, Lin F, Qin B, et al. Polymyositis/dermatomyositis and malignancy risk: a metaanalysis study. J Rheumatol 2015; 42:282.
Chow WH, Gridley G, Mellemkjaer L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6:9.
Buchbinder R, Forbes A, Hall S, et al. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134:1087.
Chen YJ, Wu CY, Huang YL, et al. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12:R70.
Cox NH, Lawrence CM, Langtry JA, Ive FA. Dermatomyositis. Disease associations and an evaluation of screening investigations for malignancy. Arch Dermatol 1990; 126:61.
Hill CL, Zhang Y, Sigurgeirsson B, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357:96.
Hendren E, Vinik O, Faragalla H. Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol. 2017 Oct;24(5):e429-e433.
Selva O’Callaghan A et al. Miopatías inflamatorias. Dermatomiositis, polimiositis y miositis con cuerpos de inclusión, Reumatol Clin. 2008;4(5):197-206
Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591.
Trallero-Araguás E, Labrador-Horrillo M, Selva-O'Callaghan A, et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89:47.
Chinoy H, Fertig N, Oddis CV, et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007; 66:1345.
Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65:2954.
H. Chinoy, N. Fertig, C.V. Oddis, W.E. Ollier, R.G. Cooper. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.
Ann Rheum Dis, 66 (2007), pp. 1345-1349
Taborda AL, Azevedo P, Isenberg DA. Retrospective analysis of the outcome of patients with idiopathic inflammatory myopathy: a long-term follow-up study. Clin Exp Rheumatol 2014; 32 (2): 188-93.
Smuder AJ. Exercise stimulates beneficial adaptations to diminish doxorubicin-induced cellular toxicity. Am J Physiol Regul Integr Comp Physiol. 2019;317(5):R662-R672. doi:10.1152/ajpregu.00161.2019
Baig S, Paik JJ, Inflammatory muscle disease e An update, Best Practice & Research Clinical Rheumatology, https://doi.org/10.1016/j.berh.2019.101484
Cómo citar
Descargas
Descargas
Publicado
Número
Sección
Licencia
Todos los derechos reservados.
